Reporting on market developments concerning AstraZeneca Launches $1.5 Billion Savings Plan to Fund Drug Pipeline. Industry analysts and investors are monitoring the operational, st...

Newell Brands reported a net quarterly loss despite modest revenue growth, weighed down by higher input expenses, freight headwinds, and ongoing corporate restructuring.

Renault Group has reaffirmed its full-year financial outlook, leveraging strict cost controls and an ambitious product rollout to navigate broader European automotive headwinds.

Eli Lilly posted significant revenue gains driven by unprecedented global demand for its blockbuster treatments Mounjaro and Zepbound, solidifying its leadership in the metabolic therapeutics market.

Hyundai Motor reported a drop in quarterly net profit and trimmed its forward guidance amid softening vehicle demand, rising sales incentives, and fierce global EV competition.

Stellantis shares surged as leadership launched an aggressive turnaround initiative to clear dealer inventories and restore sales momentum for its flagship Jeep brand.

Mercedes-Benz is offering voluntary severance packages to administrative staff as weakening global demand and intense EV competition weigh on margins.

Sandoz shares slipped following a conservative sales forecast, prompting fresh questions about pricing power and volume growth in the generic drug sector.

Biogen swung to a quarterly net loss even as top-line revenue advanced, driven by new product launches and heavy pipeline realignment expenses.

Automakers are abandoning high-budget, cinematic television commercials as margin pressures, electric vehicle transitions, and digital ROI demand frugal precision.

Swiss pharmaceutical powerhouse Roche is ramping up its oncology pipeline, targeting critical gaps in lung cancer care across key emerging markets.

European and Indo-Pacific allies are pouring billions into domestic rocket programs and satellite constellations to end critical strategic reliance on Elon Musk's SpaceX.